Capecitabine: the new generation of fluoropyrimidines in colorectal cancer

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Cilia. 54, 8–29 (2004).
   Google Scholar
• American Cancer Society. 2004 Cancer Facts and Figures. American Cancer Society, NY, USA (2004).
   Google Scholar
• Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncoll 16, 301–308 (1998).
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncoll 16, 3537–3541 (1998).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. 1 Clin Oncoll 22, 23–30 (2004).
   Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or thereverse sequence in advanced colorectalcancer: a randomized GERCOR study.Clin. Oncoll 22,229–237 (2004).
   Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Clin. Oncol. 21, 60–65 (2003).
   Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl. J Med. 350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl. J Med. 350, 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• ••Combination chemotherapy with 5-fluorouracilileucovorin/oxaliplatin (FOLFOX4) is superior to standard 5-fluorouracil (5-FU)/leucovorin (LV) in adjuvant treatment of colorectal cancer.
   Google Scholar
• Sargent DJ, Wieand S, Benedetti J et al. Disease-free survival (DFS) vs. overall survival (OS) as a primary end point for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 3502).
   Google Scholar
• Wolmark N, Wieand S, Lembersky B et al. A Phase III trial comparing oral UFT to FULV in stage II and II carcinoma of the colon: results of NSABP Protocol C-06. Proc Am. Soc. Clin. Oncol. (2004) (Abstract 3508).
   Google Scholar
• Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Etmj Cancer 34, 1274–1281 (1998).
   Google Scholar
• Budman DR, Meropol NJ, Reigner B et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. Clin Oncol. 16, 1795–1802 (1998).
   Google Scholar
• Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chernother. Pharmacol. 45, 291–297 (2000).
   PubMed Web of Science ®Google Scholar
• Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 40, 85–104 (2001).
   PubMed Web of Science ®Google Scholar
• Reigner B, Verweij J, Dirix L et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin. Cancer Res. 4, 941–948 (1998).
   PubMed Web of Science ®Google Scholar
• Judson IR, Beale PJ, Trigo JM. et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14 C-labelled drug. Invest. New Drugs 17, 49–56 (1999).
   Google Scholar
• Cassidy J, Twelves C, Cameron D et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chernother. Pharmacol. 44, 453–560 (1999).
   PubMed Web of Science ®Google Scholar
• Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chernother. Pharmacol. 49, 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Roche. Xeloda Package Insert. Roche, NY, USA (2003).
   Google Scholar
• Twelves C, Glynne-Jones R, Cassidy J et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin. Cancer Res. 5, 1696–1702 (1999).
   PubMed Web of Science ®Google Scholar
• Buyck HC, Buckley N, Leslie MD, Plowman PN. Capecitabine-induced potentiation of warfarin. Clin. Oncol. a?. Co]]. Radio].) 15, 297 (2003).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J Clin. Oncol. 18, 1337–1345 (2000).
   PubMed Web of Science ®Google Scholar
• ••Revealed equivalence of capecitabine to5-FU/LV (Mayo Clinic) regimen with an improved toxicity profile in the metastatic setting.
   Google Scholar
• Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. BE J Cancer 90, 1190–1197 (2004).
   Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin. Oncol. 19, 2282–2292 (2001).
   Google Scholar
• ••Revealed equivalence of capecitabine to5-FU/LV with an improved toxicity profile in the metastatic setting.
   Google Scholar
• Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin. Oncol. 22, 2084–2091 (2004).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin. Oncol. 21, 1307–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a Phase II trial. Cancer 100, 531–537 (2004).
   PubMed Web of Science ®Google Scholar
• Patt YZ, Lin E, Leibmann J et al. Capecitabine plus irinotecan for chemotherapy-naive patients with metastatic colorectal cancer (MCRC): US multicenter Phase II trial. Proc. Am. Soc. Cilia. Oncol. (2003) (Abstract 1130).
   Google Scholar
• Grothey A, Jordan K, Kellner 0 et al. Capecitabine/irinotecan (Caplri) and capecitabine/oxaliplatin (Cap0x) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomized Phase II study. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 3534).
   Google Scholar
• ••Combination therapy with capecitabine replacing infusional 5-FU demonstrates no difference in efficacy for patients with metastatic colorectal cancer treated second line.
   Google Scholar
• Borner MM, Dietrich D, Stupp R et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin. Oncol. 20, 1759–1766 (2002).
   PubMed Web of Science ®Google Scholar
• Carreca I, Comella P, Maiorino L et al. Oral capecitabine plus oxaliplatin (XELOX regimen) in elderly patients with advanced colorectal carcinoma (ACC). Southern Italy Co-operative Oncology Group (SICOG 0108) Phase II study. Proc Am. Soc. Cilia. Oncol. (2003) (Abstract 2939).
   Google Scholar
• Cassata A, Stani SC, AM M et al. Ongoing Phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 573).
   Google Scholar
• Schleucher N, Tewes M, Achterrath W et al. Extended Phase I Study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am. Soc. Cilia. Oncol. (2001) (Abstract 561) .
   Google Scholar
• Slater S, Shamash J, Gallagher C et al. A Phase I/II study of CPT-11 in combination with capecitabine as first line chemoterapy for metastatatic colorectal cancer (mcRq. Proc. Am. Soc. Clin. Oncol. (2002) (Abstract 643).
   Google Scholar
• Patt YZ, Liebmann J, Diamandidis D et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (mcRq: final safety findings from a Phase II trial. Proc. Am. Soc. Oncol. (2004) (Abstract 3602).
   Google Scholar
• Munoz A, Salut A, Escudero P et al. Irinotecan (CPT-11) and capecitabine (C) as first line treatment of locally advanced or metastatic colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1271).
   Google Scholar
• Borner MM, Dietrich D, Popescu R et al. A randomized Phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC). Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 1068).
   Google Scholar
• Cassidy J, Scheithauer W McKendrick J et al. Capecitabine (X) vs. bolus 5-Hilleucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a Phase III trial. Proc. Am. Soc. Cum Oncol. (2004) (Abstract 3509).
   Google Scholar
• ••Equivalence of capecitabine and 5-EU/LVwas established in the adjuvant setting.
   Google Scholar
• Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322–1327 (2000).
   Google Scholar
• Meropol NJ, Gold PJ, Diasio RB et al. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehyrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus iriontecan in patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 3520).
   Google Scholar
• •• Thymidine phosphorylase expression correlates with response to therapy.
   Google Scholar
• Park DJ, Stoehlmacher J, Zhang W et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17, 46–49 (2002).
   PubMed Web of Science ®Google Scholar